Collaborative Agreements (Details) - USD ($)	1 Months Ended
Dec. 31, 2020	Sep. 30, 2020	Dec. 31, 2021
Collaborative Agreements (Details) [Line Items]
Grand award,description	During the year ended December 31, 2020, the Company was awarded a $500,000 grant from the Amyotrophic Lateral Sclerosis (“ALS”) Association to fund a study of the efficacy of XPro to reverse ALS in vitro and to fund a study of the efficacy of XPro to protect against ALS model phenotypes in vivo.	the Company was awarded a grant of up to $2.9 million from the National Institutes of Health (“NIH”). The grant will support a Phase 2 study of XPro in patients with treatment resistant depression. As of December 31, 2021, the Company has not received any proceeds pursuant to this grant.
Grants received	$ 200,000		$ 300,000
ALS [Member]
Collaborative Agreements (Details) [Line Items]
Deferred liabilities			$ 257,000

Amount of deferred tax liability attributable to taxable temporary differences classified as other.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319

Name:	us-gaap_DeferredTaxLiabilitiesOther
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant